Skip to content

Study for effect of classic prescription Danggui Shaoyao Powder in the treatment of Wet-stasis syndrome Non-alcoholic Fatty Liver Disease

Study for effect of classic prescription Danggui Shaoyao Powder in the treatment of Wet-stasis syndrome Non-alcoholic Fatty Liver Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000002925
Enrollment
Unknown
Registered
2020-01-15
Start date
2020-02-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease

Interventions

Sponsors

Shuguang Hospital affiliated to Shanghai University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic standard of the nonalcoholic fatty liver disease; 2. Meet the standard of Wet-stasis syndrome; 3. Aged 18-65 years old; 4. ALT is greater than the upper limit of normal (male> 50IU / L, female> 40 IU / L), and less than or equal to 5 times the upper limit of normal; 5. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who have used other liver-protecting and enzyme-lowering drugs which might affect the efficacy evaluation in the past 3 months; 2. Patients with alcoholic fatty liver (male alcohol intake> 20g / d, female alcohol intake> 10g / d);Patients with cirrhosis, HBV, HCV and other liver diseases; Patients with autoimmune liver disease; People who are taking any drug which might cause fatty liver; 3. Those with normal liver function; 4. Those who have undergone gastrointestinal weight loss surgery in the past year or those who have lost weight by more than 10% after taking weight-loss drugs within the past 3 months; 5. Pregnant women, lactating women, patients with primary diseases such as cardiovascular, lung, kidney, hematopoietic system, and other major diseases such as malignant tumors.

Design outcomes

Primary

MeasureTime frame
MRI-PDFF;serum activity of ALT;

Secondary

MeasureTime frame
serum activity of GGT;waistline;serum levels of LDL;SF-36;Abdominal Fibroscan CAP;TCM Syndrome Points;fasting blood-glucose;serum levels of TG;insulin resistance index;serum levels of HDL-C;fasting insulin;serum levels of TC;BMI;serum activity of AST;weight;

Countries

China

Contacts

Public ContactQin Feng
fengqin1227@163.com+86 13764380682

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026